ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near Madrid, MD, ESP:

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Benralizumab
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 80 other locations

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomogr...

Active, not recruiting
Asthma
Combination Product: Benralizumab

Phase 4

AstraZeneca
AstraZeneca

Madrid, Spain and 33 other locations

This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma...

Active, not recruiting
Asthma
Biological: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 76 other locations

Locations recently updated

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 99 other locations

to budesonide in children from 6 to less than 12 years of age with asthma.* The study duration will be up to 37 weeks including an investiga...

Enrolling
Asthma
Drug: QMF149
Drug: Budesonide

Phase 3

Novartis
Novartis

Madrid, Spain and 46 other locations

This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 141 other locations

BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma...

Enrolling
Asthma
Drug: AZD4604
Other: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 141 other locations

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: povorcitinib
Other: placebo

Phase 2

Incyte
Incyte

Madrid, Spain and 95 other locations

and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma...

Enrolling
Asthma, Allergic
Rhinoconjunctivitis
Biological: 30,000 MG01 + 10,000 T517
Other: Placebo

Phase 3

Inmunotek

Madrid, Spain and 25 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 353 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems